Autotaxin

GENEVA, March 09, 2022 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical-stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, will present preclinical data on its next-generation…

GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode…

Safety, pharmacokinetic and pharmacodynamic readouts expected Q4 2021IOA-289 first ATX inhibitor to progress to clinic in oncology GENEVA, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company…